{"id":391079,"date":"2016-08-26T00:00:00","date_gmt":"2016-08-26T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0011-2016-biopharma-spondyloarthritis-access-and-reimbursement-us-2016\/"},"modified":"2026-04-29T05:27:11","modified_gmt":"2026-04-29T05:27:11","slug":"acreim0011-2016-biopharma-spondyloarthritis-access-and-reimbursement-us-2016","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0011-2016-biopharma-spondyloarthritis-access-and-reimbursement-us-2016\/","title":{"rendered":"Spondyloarthritis | Access and Reimbursement | US | 2016"},"content":{"rendered":"<p>The U.S. therapy market for the SpA indications PsA, AS, and\u00a0nr-AxSpA is becoming increasingly crowded as new biologics and\u00a0SMIs offering novel MOAs\u00a0enter the market and compete for preferential formulary placement and market share against established TNF-\u03b1 inhibitors. With the additional threat of biosimilar versions of market leaders on the horizon, this research aims to provide a detailed, expanded analysis of the market access environment for SpA in the United States. Insight on the interaction between physicians and payers, the impact of reimbursement decisions on drug uptake, and the expectations for emerging SpA therapies will help clarify the current\u2014and future\u2014state of the SpA\u00a0therapy market for drug developers hoping to penetrate this space.<\/p>\n","protected":false},"template":"","class_list":["post-391079","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriatic-arthritis","biopharma-geography-us","biopharma-date-858"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391079\/revisions"}],"predecessor-version":[{"id":394202,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/391079\/revisions\/394202"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=391079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}